Cryoport Exceeds 2025 Revenue Guidance with Strong Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CYRX?
Source: seekingalpha
- Revenue Growth Highlight: Cryoport reported $176.2 million in revenue from continuing operations for 2025, exceeding the high end of prior guidance, which reflects sustained momentum across core markets and is expected to bolster investor confidence.
- Segment Performance: In Q4, commercial cell and gene therapy revenue grew 29% year-over-year to $33.4 million, while clinical trial revenue increased 14% to $47.1 million, indicating strong performance in the rapidly evolving biopharmaceutical sector.
- Strategic Investments and Partnerships: The company made strategic investments in its Global Supply Chain Centers in Paris and California, alongside new collaborations with DHL, Cardinal Health, and Parexel, which will lay the groundwork for future market expansion and enhanced service capabilities.
- Future Outlook: Management anticipates full-year 2026 revenue guidance of $190 million to $194 million and aims to achieve positive adjusted EBITDA in the second half of 2026, demonstrating confidence in future growth and a continued focus on commercial cell therapy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CYRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CYRX
Wall Street analysts forecast CYRX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.210
Low
11.00
Averages
11.00
High
11.00
Current: 8.210
Low
11.00
Averages
11.00
High
11.00
About CYRX
Cryoport, Inc. provides temperature-controlled supply chain solutions for the Life Sciences, with an emphasis on regenerative medicine. The Company supports biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products. Its integrated supply chain platform includes the Cryoportal Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, and cryogenic systems. The Company's segments include Life Sciences Services and Life Sciences Products. The Company's Life Sciences Services segment provides cryogenic biostorage within the life science industry through direct sales. Its Life Sciences Products segment manufactures and sells cryogenic freezers, cryogenic dewars and accessories within the life science industry through direct sales or a distribution network.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cryoport Exceeds 2025 Revenue Guidance with Strong Growth
- Revenue Growth Highlight: Cryoport reported $176.2 million in revenue from continuing operations for 2025, exceeding the high end of prior guidance, which reflects sustained momentum across core markets and is expected to bolster investor confidence.
- Segment Performance: In Q4, commercial cell and gene therapy revenue grew 29% year-over-year to $33.4 million, while clinical trial revenue increased 14% to $47.1 million, indicating strong performance in the rapidly evolving biopharmaceutical sector.
- Strategic Investments and Partnerships: The company made strategic investments in its Global Supply Chain Centers in Paris and California, alongside new collaborations with DHL, Cardinal Health, and Parexel, which will lay the groundwork for future market expansion and enhanced service capabilities.
- Future Outlook: Management anticipates full-year 2026 revenue guidance of $190 million to $194 million and aims to achieve positive adjusted EBITDA in the second half of 2026, demonstrating confidence in future growth and a continued focus on commercial cell therapy.
See More
Cryoport (CYRX) Q4 2025 Earnings Call Transcript
See More
CryoPort Q4 Earnings Beat Expectations Despite EPS Miss
- Earnings Highlights: CryoPort reported a Q4 GAAP EPS of -$0.27, missing expectations by $0.06; however, revenue reached $45.5 million, reflecting a 9.6% year-over-year increase and beating market expectations by $2.58 million, indicating robust growth in the biopharmaceutical logistics sector.
- Annual Revenue Guidance: The company provided a revenue guidance for FY 2026 of $190 million to $194 million, projecting an 8% to 10% year-over-year growth, which reflects a positive outlook on future market demand and may attract more investor interest in its long-term growth potential.
- Market Reaction: Despite the EPS miss, the strong revenue performance could boost investor confidence in the short term, potentially driving the stock price up and improving the company's image in the capital markets.
- Industry Outlook: With the ongoing expansion of the biopharmaceutical industry, CryoPort's growth potential is significant, particularly in cold chain logistics and biological sample transportation, which is expected to further solidify its market position and drive future business development.
See More
Cryoport Exceeds Revenue Guidance in 2025 Financial Results
- Significant Revenue Growth: Cryoport reported full-year revenue of $176.2 million for 2025, exceeding guidance and reflecting strong demand in the cell and gene therapy market, particularly with commercial CGT support revenue increasing 29% year-over-year to $33.4 million, showcasing the company's leadership in a rapidly growing sector.
- Clinical Trial Support Innovation: As of 2025, Cryoport supported a record 760 global clinical trials, an increase of 59 from 2024, with approximately 70% being CGT trials, indicating the company's ongoing expansion in clinical research and robust market demand.
- Strategic Partnership Enhances Competitiveness: Cryoport formed a strategic partnership with DHL Group, which included DHL's acquisition of CRYOPDP, expected to provide substantial capital infusion and enhance the company's competitive profile in the EMEA and APAC regions, supporting future growth strategies.
- Optimistic Future Outlook: Cryoport anticipates full-year revenue guidance of $190 million to $194 million for 2026, reflecting confidence in future market opportunities while continuing to focus on improving operational efficiency and profitability.
See More
CryoPort to Announce Q4 Earnings on March 3rd
- Earnings Announcement Date: CryoPort is set to release its Q4 earnings on March 3rd after market close, with stakeholders keenly awaiting the results to gauge the company's future growth potential.
- EPS Expectations: The consensus EPS estimate stands at -$0.21, reflecting a 50% year-over-year improvement, indicating the company's efforts to enhance profitability despite challenging conditions.
- Revenue Decline Forecast: The anticipated revenue for Q4 is $42.92 million, representing a 28% year-over-year decrease, which highlights the challenges faced by the company amid market competition and demand fluctuations, potentially impacting its short-term financial health.
- Market Attention: Investors and analysts will closely monitor this earnings report to assess CryoPort's financial performance and strategic direction, particularly regarding its adaptability in the current economic landscape.
See More
Cryoport Launches Fusion 800 Series, Revolutionizing Cryogenic Storage Technology
- Technological Innovation: Cryoport has launched the Fusion 800 Series through its MVE Biological Solutions division, which operates without the need for continuous liquid nitrogen, providing a compact and efficient cryogenic storage solution that addresses the space and infrastructure demands of traditional systems.
- Design Advantages: The Fusion 800's compact design (32 inches wide) allows it to fit through standard door frames, avoiding costly facility modifications, significantly reducing operational complexity while enhancing safety and flexibility.
- Financial Performance: In November, Cryoport reported Q3 revenue of $44.2 million, exceeding analyst expectations of $41.36 million, with a year-over-year growth of 15%, including a 36% increase in Commercial Cell and Gene Therapy, indicating strong market demand.
- Future Outlook: Cryoport raised its fiscal 2025 revenue guidance to a range of $170 million to $174 million, reflecting confidence in the market potential of the Fusion 800 Series and the overall growth of the company.
See More
Cryoport Exceeds 2025 Revenue Guidance with Strong Growth
- Revenue Growth Highlight: Cryoport reported $176.2 million in revenue from continuing operations for 2025, exceeding the high end of prior guidance, which reflects sustained momentum across core markets and is expected to bolster investor confidence.
- Segment Performance: In Q4, commercial cell and gene therapy revenue grew 29% year-over-year to $33.4 million, while clinical trial revenue increased 14% to $47.1 million, indicating strong performance in the rapidly evolving biopharmaceutical sector.
- Strategic Investments and Partnerships: The company made strategic investments in its Global Supply Chain Centers in Paris and California, alongside new collaborations with DHL, Cardinal Health, and Parexel, which will lay the groundwork for future market expansion and enhanced service capabilities.
- Future Outlook: Management anticipates full-year 2026 revenue guidance of $190 million to $194 million and aims to achieve positive adjusted EBITDA in the second half of 2026, demonstrating confidence in future growth and a continued focus on commercial cell therapy.
See More
Cryoport (CYRX) Q4 2025 Earnings Call Transcript
See More
CryoPort Q4 Earnings Beat Expectations Despite EPS Miss
- Earnings Highlights: CryoPort reported a Q4 GAAP EPS of -$0.27, missing expectations by $0.06; however, revenue reached $45.5 million, reflecting a 9.6% year-over-year increase and beating market expectations by $2.58 million, indicating robust growth in the biopharmaceutical logistics sector.
- Annual Revenue Guidance: The company provided a revenue guidance for FY 2026 of $190 million to $194 million, projecting an 8% to 10% year-over-year growth, which reflects a positive outlook on future market demand and may attract more investor interest in its long-term growth potential.
- Market Reaction: Despite the EPS miss, the strong revenue performance could boost investor confidence in the short term, potentially driving the stock price up and improving the company's image in the capital markets.
- Industry Outlook: With the ongoing expansion of the biopharmaceutical industry, CryoPort's growth potential is significant, particularly in cold chain logistics and biological sample transportation, which is expected to further solidify its market position and drive future business development.
See More
Cryoport Exceeds Revenue Guidance in 2025 Financial Results
- Significant Revenue Growth: Cryoport reported full-year revenue of $176.2 million for 2025, exceeding guidance and reflecting strong demand in the cell and gene therapy market, particularly with commercial CGT support revenue increasing 29% year-over-year to $33.4 million, showcasing the company's leadership in a rapidly growing sector.
- Clinical Trial Support Innovation: As of 2025, Cryoport supported a record 760 global clinical trials, an increase of 59 from 2024, with approximately 70% being CGT trials, indicating the company's ongoing expansion in clinical research and robust market demand.
- Strategic Partnership Enhances Competitiveness: Cryoport formed a strategic partnership with DHL Group, which included DHL's acquisition of CRYOPDP, expected to provide substantial capital infusion and enhance the company's competitive profile in the EMEA and APAC regions, supporting future growth strategies.
- Optimistic Future Outlook: Cryoport anticipates full-year revenue guidance of $190 million to $194 million for 2026, reflecting confidence in future market opportunities while continuing to focus on improving operational efficiency and profitability.
See More
CryoPort to Announce Q4 Earnings on March 3rd
- Earnings Announcement Date: CryoPort is set to release its Q4 earnings on March 3rd after market close, with stakeholders keenly awaiting the results to gauge the company's future growth potential.
- EPS Expectations: The consensus EPS estimate stands at -$0.21, reflecting a 50% year-over-year improvement, indicating the company's efforts to enhance profitability despite challenging conditions.
- Revenue Decline Forecast: The anticipated revenue for Q4 is $42.92 million, representing a 28% year-over-year decrease, which highlights the challenges faced by the company amid market competition and demand fluctuations, potentially impacting its short-term financial health.
- Market Attention: Investors and analysts will closely monitor this earnings report to assess CryoPort's financial performance and strategic direction, particularly regarding its adaptability in the current economic landscape.
See More
Cryoport Launches Fusion 800 Series, Revolutionizing Cryogenic Storage Technology
- Technological Innovation: Cryoport has launched the Fusion 800 Series through its MVE Biological Solutions division, which operates without the need for continuous liquid nitrogen, providing a compact and efficient cryogenic storage solution that addresses the space and infrastructure demands of traditional systems.
- Design Advantages: The Fusion 800's compact design (32 inches wide) allows it to fit through standard door frames, avoiding costly facility modifications, significantly reducing operational complexity while enhancing safety and flexibility.
- Financial Performance: In November, Cryoport reported Q3 revenue of $44.2 million, exceeding analyst expectations of $41.36 million, with a year-over-year growth of 15%, including a 36% increase in Commercial Cell and Gene Therapy, indicating strong market demand.
- Future Outlook: Cryoport raised its fiscal 2025 revenue guidance to a range of $170 million to $174 million, reflecting confidence in the market potential of the Fusion 800 Series and the overall growth of the company.
See More
